Target Information

Target General Infomation
Target ID
T75643
Former ID
TTDI01990
Target Name
Pattern recognition receptor NOD2
Gene Name
NOD2
Synonyms
Caspase recruitment domaincontaining protein 15; Inflammatory bowel disease protein 1; Nucleotidebinding oligomerization domaincontaining protein 2; NOD2
Target Type
Clinical Trial
Disease Autoimmune diabetes [ICD10: E08-E13]
Bacillus anthracis infection [ICD10: A22]
HBV infection [ICD9: 070.2-070.3; ICD10: B16, B18.0, B18.1]
Function
Recognizes muramyl dipeptide (MDP) constituents of bacterial peptidoglycans and plays a key role in gastrointestinal immunity: upon stimulation, binds the proximal adapter receptor- interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling, leading to activate the transcription of hundreds of genes involved in immune response.
UniProt ID
Q9HC29
Sequence
MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWL
LSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLH
GCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECDEIRLPIFTPSQR
ARRLLDLATVKANGLAAFLLQHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTY
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGE
AGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLFEHCCWPDVGQ
EDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDPTSVQTLLFNLLQGNLLKNAR
KVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALH
GLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLL
RGRLPTLLHLGRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLE
FLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQASEGKDSSVA
ALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTECA
ALAFVLQHLRRPVALQLDYNSVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECAL
HCEQLQKLALFNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTS
LQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRG
NTFSLEEVDKLGCRDTRLLL
Drugs and Mode of Action
Drug(s) MIS-416 Drug Info Phase 2 Autoimmune diabetes [549949]
SB-9200 Drug Info Phase 1 HBV infection [524226]
Modulator MIS-416 Drug Info
SB-9200 Drug Info
Agonist muramyl dipeptide Drug Info [543479]
Pathways
KEGG Pathway NOD-like receptor signaling pathway
TNF signaling pathway
Shigellosis
Tuberculosis
Inflammatory bowel disease (IBD)
Pathway Interaction Database Canonical NF-kappaB pathway
Reactome NOD1/2 Signaling Pathway
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Interleukin-1 signaling
activated TAK1 mediates p38 MAPK activation
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
WikiPathways MAP kinase activation in TLR cascade
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Interleukin-1 signaling
NOD pathway
References
Ref 524226ClinicalTrials.gov (NCT01803308) A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naive Adults With Chronic Hepatitis C Infection. U.S. National Institutes of Health.
Ref 549949Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. January 31, 2014.
Ref 543479(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1763).
Ref 549949Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. January 31, 2014.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.